Stephanie McArdle (0000-0001-6929-9782)

Personal information

Biography

Dr. McArdle is a Senior Research Scientist in Tumour Immunology who leads the development of T-cell vaccines against cancers. In particular, Dr. McArdle has identified a mutated Prostatic Acid Phosphatase, PAP, derived sequence, which, when injected with CAF09, a strong adjuvant (kind gift from Dr. Dennis Christensen) has now been granted patent in Europe and in the US. Preclinical works are ongoing to gather the necessary data for a phase-0/I clinical trial for the treatment of hormone resistant prostate cancer. Dr. McArdle is also working on a HAGE- and mutated NY-ESO1-derived peptide sequences for the treatment of Triple Negative Breast Cancer (TNBC).
Dr. McArdle collaborates with many European laboratories which offers strong adjuvants such as CAF09 (Dr. Dennis Christensen, Serum Institute, Denmark), Immune-complexes (Dr. Sara Mangsbo (Upsala University, Sweden), L-Dopa, a precursor of melanin (Dr. Antoine Carpentier, Université Paris Descartes, Paris, France) as well as UK collaborator such as Prof. Lindy Durrant (Immunobody®, Nottingham University).
Dr. McArdle has also a particular interest in the effect of exercise, mental health and gut microbiota on the immune system of cancer patients and a study in ongoing in prostate cancer patients to assess the level of inflammation related molecules, the psychological status and the gut permeability of prostate benign vs cancer patients. She is keen to emphasise the importance of one’s life style on one’s health. She has previously organised three “Health and Well Being” days dedicated to promote self-help.

Activities

Collapse all

Nottingham Trent University: Nottingham, Nottinghamshire, GB

2006-10-01 to present | Senior Research Scientist in Tumour Immunology (The John van Geest Cancer Research Centre)

Employment

Stephanie McArdle

https://orcid.org/0000-0001-6929-9782

Personal information

Websites & social links

Other IDs

Keywords

Countries

Biography

Activities

Employment (1)

Nottingham Trent University: Nottingham, Nottinghamshire, GB

Education and qualifications (4)

Nottingham Trent University: Nottingham, Nottinghamshire, GB

Royal Hallamshire Hospital: Sheffield, Sheffield, GB

Manchester Metropolitan University: Manchester, Greater Manchester, GB

Institut Universitaire de Technologie PARIS XII, Creteil: Creteil, Parix XII, FR

Funding (2)

Towards the Development of a new Immunotherapy for the Treatment of Glioblastoma multiforme (GBM)

Research towards the next generation of immunicological therapeutic vaccines and delivery systems for the treatment of Uveal melanoma.

Works (50 of 58)

Anticancer actions of carnosine in cellular models of prostate cancer

Robust formation of optimal single spheroids towards cost‐effective in vitro three‐dimensional tumor models

A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer

Controlled release of carnosine from poly(lactic-co-glycolic acid) beads using nanomechanical magnetic trigger towards the treatment of glioblastoma

Multi-Omic Analysis of Two Common P53 Mutations: Proteins Regulated by Mutated P53 as Potential Targets for Immunotherapy

A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8<sup>+</sup> T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice

Swift Formation of Optimal Single Spheroids towards In-Vitro 3-Dimensional Tumour Models

Synthesis and Functionalisation of Superparamagnetic Nano-Rods towards the Treatment of Glioblastoma Brain Tumours

Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer

Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention

Immune Landscape of Breast Cancers

Identifying the Presence of Prostate Cancer in Individuals with PSA Levels <20 ng ml-1 Using Computational Data Extraction Analysis of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.

Abstracts from the 4th ImmunoTherapy of Cancer Conference: Prague, Czech Republic. 20–22 March 2017.

High Reproducibility of ELISPOT Counts from Nine Different Laboratories.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Assessing the toxic effects of DMSO on cord blood to determine exposure time limits and the optimum concentration for cryopreservation.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer

Log-Normal ELISPOT spot size distribution permits count harmonization among different laboratories.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice

Prostate cancer: Important steps and considerations in the design of therapeutic vaccines

Avoiding room temperature storage and delayed cryopreservation provide better postthaw potency in hematopoietic progenitor cell grafts

Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: Dysregulation of alternative splicing in cancer

Identification of novel breast cancer-associated transcripts by uniGene database mining and gene expression analysis in normal and malignant cells

Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage

The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo

Tenth International Conference on Progress in Vaccination against cancer (PIVAC 10), Cambridge, UK, 27th-30th September 2010: New hopes and strategies for cancer vaccines

HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers

Ninth international conference on progress in vaccination against cancer (PIVAC 9), 8-10 October 2009, Sofia, Bulgaria

HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers.

Cancer vaccines: Uses of HLA transgenic mice compared to genetically modified mice

Cancer/testis antigens for therapeutic use

CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model

ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring-even in hands of ELISPOT-inexperienced investigators

Estimation of peptide concentration by a modified bicinchoninic acid assay

Non-X-linked cancer/testis antigens: Identification, expression profile and immunogenicity

Tumor immunology: New perspectives

Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: Is it still viable?

Cancer/testis antigens for therapeutic use.

DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines

Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries.

Overview of prostate biomarkers as potential targets for immunotherapy

HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: Identification of several MHC class I/II HAGE-derived immunogenic peptides

Identification of a novel prostate cancer-associated tumor antigen

Identification of immunogenic MHC class II tyrosinase-derived peptides using HLA-DR1 and HLA-DR4 transgenic mice

The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines

Immunity to tumour antigens

Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRβ1*0101- and HLA-DRβ1*0401-restricted epitope from p53

Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC-mGM-CSF

Anti-tumour therapeutic efficacy of OX40L in murine tumour model

A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions

Peer review (3 reviews for 3 publications/grants)

Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRβ10101- and HLA-DRβ10401-restricted epitope from p53